Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

The latest declines in Eli Lilly's stock price occurred in response to management's presentation at the annual JPMorgan Healthcare conference. On Jan. 14, CEO David Ricks told investors that 2024 ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and ...

Lily Collins, and Larry David are donating their time for a good cause. They’re participating in a Charitybuzz campaign benefiting students, individuals, and communities devastated by the ...

Eli Lilly (LLY) announced that the FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease in adults. Omvoh is now approved in the U.S. for two types of ...

We bring on Ricks for a wide-ranging conversation about his views on the incoming Trump administration, the effects of Medicare’s drug price negotiation, Lilly’s recent disappointing guidance ...

Eli Lilly forecasts $45 billion in 2024 revenue ... During the conference, David Ricks outlined two reasons for the guidance update: The diabetes GLP market, in December, outperforms the rest ...

CEO Dave Ricks said Lilly is now considering expanding the vial offering. “We’d like to lower the entry cost and we’d like to have more doses available. That’s not something we’re ...

Eli Lilly’s CEO Dave Ricks acknowledged the challenges in predicting growth in the rapidly expanding GLP-1RA market. During the conference presentation, he said: “It’s always disappointing to miss ...

Shares in Meta fell more than 2% on Tuesday, following reports that the social media company is planning to cut around 5% of its workforce through performance-based terminations. According to a ...